Analysis of the Role of IgE Proteoforms in Health and Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-01-01

Study Completion Date

2029-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this observational study is to evaluate the role of IgE proteoforms in healthy volunteers and in patients with type I allergy, patients with chronic spontaneous urticaria, patients with a recent history of anaphylaxis, patients with mastocytosis, patients with hereditary alpha tryptasemia, patients with X-linked agammaglobulinemia (XLA), and patients undergoing desensitization for venom or medication allergy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study in Allergic Adults to Support the Development of Immunological Assays

NCT01320137

Immunologic Tests

COMPLETED NA

Prevalence of Food Allergies to Proteins From Different Legumes

NCT01728168

Food Allergy

COMPLETED

Mucosal IgE to Improve Diagnosis of Food Allergy and Food Hypersensitivity

NCT05259826

Food Allergy Food Hypersensitivity

RECRUITING NA

Biomarkers in Food Allergy Diagnosis

NCT04604912

Allergy;Food

COMPLETED

The Effect of Per Oral Immunotherapy in Severe Milk, Peanut and Egg Allergy in Adults

NCT03361072

Food Allergy

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anaphylaxis Mastocytosis X-linked Agammaglobulinaemia Venom Allergy Chronic Spontaneous Urticaria (CSU) Type I Allergy Medication Allergy Healthy Control Hereditary Alpha-Tryptasemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy controls

Blood sample collection

Intervention Type OTHER

Blood sample collection

Patients with type I allergy

Including medication allergy, venom allergy, food allergy, allergic rhinitis

Blood sample collection

Intervention Type OTHER

Blood sample collection

Patients with chronic spontaneous urticaria

With or without omalizumab

Blood sample collection

Intervention Type OTHER

Blood sample collection

Patients with a recent history of anaphylaxis

In whom serial sampling can be performed

Blood sample collection

Intervention Type OTHER

Blood sample collection

Patients undergoing desensitization for venom allergy

Blood sample collection

Intervention Type OTHER

Blood sample collection

Patients undergoing desensitization for medication allergy

Blood sample collection

Intervention Type OTHER

Blood sample collection

Patients with mastocytosis

Blood sample collection

Intervention Type OTHER

Blood sample collection

Patients with hereditary alpha tryptasemia

Blood sample collection

Intervention Type OTHER

Blood sample collection

Patients with X-linked agammaglobulinemia (XLA)

Blood sample collection

Intervention Type OTHER

Blood sample collection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood sample collection

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* CSU and type I allergic diseases (including anaphylaxis and desensitization), atopic dermatitis, mastocytosis, XLA and HaT (informed consent, age: any available adult subject, gender: any available subject, clinical phenotype and specific information about the allergy (e.g. severity, medication, medical history, laboratory testing)
* Healthy controls (informed consent, age matched to the allergic patients, gender matched to the allergic patients, patient-reported symptoms related to allergy to aeroallergens, food, drugs, hymenoptera venom, CSU)